Abstract
ObjectiveThe CAPSTONE-1 trial demonstrated that adebrelimab-based immunotherapy yielded a favourable survival benefit compared with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have